In depression, MAO-A inhibitors reduce the central metabolism of serotonin and noradrenaline, while enhanced MAO-A density in several brain regions has been implicated in the depletion of monoamine levels in major depression [15]. Here, MAOA is linked to depressive symptom measurement.